Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624732 | 1.00 | CES2 (0.50) | CES2ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL624733 | 1.00 | CES2 (0.50) | CES2ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL13930327 | 0.83 | CES2 (0.53) | CES2ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL19592309 | 0.81 | CES2 (0.58) | CES2ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL10958300 | 0.81 | CES2 (0.50) | CES2ALDH1A1NPSR1SRD5A2MAOB | |
| SCHEMBL10958305 | 0.81 | CES2 (0.50) | CES2ALDH1A1NPSR1SRD5A2MAOB | |
| SCHEMBL26962847 | 0.81 | CES2 (0.50) | CES2ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL20806278 | 0.80 | CES2 (0.56) | CES2ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL625016 | 0.80 | NR4A1 (0.54) | CES2SRD5A2MAOBNQO2 | |
| SCHEMBL625015 | 0.80 | NR4A1 (0.54) | CES2SRD5A2MAOBNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | CES2 4412/4885ALDH1A1 2560/4885MEN1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.